Perfusion Imaging

Perfusion Imaging

The perfusion imaging market is expected to register a CAGR of approx. 4.3% over the period of 2023-2030. Perfusion imaging is a medical imaging technique used to assess blood flow to tissues and organs in the body. It is particularly valuable in diagnosing and monitoring conditions such as stroke, heart disease, and certain types of cancer. The growing demand for perfusion imaging can be attributed to the increasing incidence of cardiovascular diseases are the key factors which boost the adoption around the globe. For instance, according to the CDC, One person dies every 33 seconds in the United States from cardiovascular disease. About 695,000 people in the United States died from heart disease in 2021—that’s 1 in every 5 deaths. Furthermore, ongoing advancements in imaging technology, including higher resolution and more efficient imaging techniques, have been a key driver. Innovations in MRI, CT, and nuclear medicine have enhanced the capabilities of perfusion imaging. Moreover, perfusion imaging plays a crucial role in oncology for the detection and evaluation of tumours. The rising incidence of cancer cases worldwide has driven the demand for perfusion imaging procedures. In 2021, cancer remained a significant healthcare concern.

• Based on the type, the market has been categorized into magnetic resonance imaging, computed tomography, ultrasound, and others. Among them, the magnetic resonance imaging segment is expected to grow at a higher CAGR in the market due to its non-invasive nature, excellent soft tissue contrast, and ability to provide quantitative perfusion data. Recent developments in MRI technology, combined with new government regulations, have further contributed to the growth of this segment. For instance, in 2021, Siemens Healthineers introduced the MAGNETOM Free.Max MRI system, which features cutting-edge technology for neuroimaging applications. This system offers advanced perfusion imaging capabilities for neurological assessments.
• Based on the application, the market has been categorized into ventilation-perfusion imaging, myocardial perfusion imaging, functional brain imaging, and tumour detection. Among them, the myocardial perfusion imaging segment is expected to grow at a higher CAGR in the market due to Cardiovascular diseases, including coronary artery disease (CAD), are a leading cause of morbidity and mortality worldwide. MPI plays a crucial role in diagnosing and evaluating these conditions, driving demand for this segment. For instance, Siemens Healthineers introduced the syngo.CT Cardiac Function, a software application designed to assess cardiac function, including myocardial perfusion, using CT scans. While this development is not specific to MPI using nuclear medicine, it exemplifies the industry's efforts to expand the capabilities of cardiac imaging.
• Based on the end-user, the market has been categorized into hospitals, diagnostic center, and research institutes. Among them, the hospital category is to witness higher adoption of perfusion imaging during the forecast period. The hospitals segment is a key driver of the perfusion imaging market due to its central role in healthcare delivery and the diagnosis and treatment of various medical conditions. In addition, Perfusion imaging is crucial for treatment planning and monitoring. Hospitals use perfusion imaging to assess the extent and severity of conditions, which helps in planning surgeries, interventions, and therapies. It aids in optimizing patient care. Moreover, In emergency situations such as stroke, myocardial infarction, and trauma, quick and accurate diagnosis is critical. Hospitals use perfusion imaging for rapid assessment, enabling timely interventions that can save lives and reduce morbidity. For example, Many hospitals worldwide continued to expand and modernize their imaging departments in 2021. They invested in advanced perfusion imaging systems, such as MRI, CT, and PET scanners, to improve patient care and diagnostic capabilities.
• For a better understanding of the market adoption of the ADNP syndrome treatment industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, and Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. The North America perfusion imaging market is expected to continue to grow in the coming years, driven by the increasing prevalence of cancer and growing awareness of perfusion imaging among healthcare professionals and the general population, development of advanced imaging techniques and the rise in treatment option. For instance, in 2020, according to American Cancer Society, Cancer is the second most common cause of death in the US, exceeded only by heart disease. around 609,360 deaths from cancer are expected in the US in 2022, which is about 1,670 deaths per day.
• Some of the major players operating in the market include Siemens Healthineers, GE Healthcare, Philips Healthcare, Bayer AG, Medtronic, Canon Medical Systems Corporation, Shimadzu Corporation, Bracco Imaging S.p.A, Neusoft Corporation, Perimed AB.